145 results
Page 3 of 8
8-K
EX-99.1
xv41fgywvx461
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm
8-K
EX-99.1
d6ktibfcqa
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
6mvi6030
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
EX-99.1
44rzwlyb cyhv1mo
28 Aug 20
Regulation FD Disclosure
10:44am
S-3ASR
fwy0 e18ux
10 Aug 20
Automatic shelf registration
5:01pm
424B5
tfxr cmuq85
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
kbhnq1kim6bogwi t2h
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
sxbwiw
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
g45xmdlz986cfxb6 0kw
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
sfaozo4ej0
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
1sfiuzt b5g
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
wdjh ic3qq9n4r8kpyt
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am